rRNA ( rrn ) Operon-Engineered Bacillus subtilis as a Feasible Test Organism for Antibiotic Discovery | Zendy

Yukinori Tanaka | Zendy; Hideaki Nanamiya | Zendy; Koichi Yano | Zendy; Koji Kakugawa | Zendy; Fujio Kawamura | Zendy; Kozo Ochi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

rRNA ( rrn ) Operon-Engineered Bacillus subtilis as a Feasible Test Organism for Antibiotic Discovery

Author(s) -

Yukinori Tanaka,

Hideaki Nanamiya,

Koichi Yano,

Koji Kakugawa,

Fujio Kawamura,

Kozo Ochi

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02604-12

Subject(s) - operon , bacillus subtilis , biology , ribosomal rna , microbiology and biotechnology , rna polymerase , rna , polymerase , antibiotics , bacteria , escherichia coli , dna , genetics , gene

Bacillus subtilis contains 10 rRNA (rrn) operons. We found that rRNA operon-engineered B. subtilis strain RIK543, with only the rrnO operon, is specifically hypersensitive to RNA polymerase inhibitors such as rifamycin SV and rifampin (80-fold and 20-fold, respectively). In pilot screening experiments, we found actinomycete isolates successfully at an incidence of 1.9% (18/945) that produced antibacterials that were detectable only with RIK543 as the test organism. Strain RIK543 may be a feasible test organism for the discovery of novel RNA polymerase inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research